Researchers at Stanford University have made significant strides in understanding amyotrophic lateral sclerosis (ALS), also known as Lou Gehrig’s disease, which leads to the death of motor neurons responsible for muscle movement and breathing. ALS typically results in progressive muscle weakness, leading to loss of mobility and independence, with most patients succumbing within three to five years of diagnosis.
The underlying processes affecting motor neurons in ALS have remained largely elusive due to the difficulty of studying these cells in living individuals. Aaron Gitler, PhD, a professor of genetics, highlighted the challenges of analyzing post-mortem motor neurons, stating, “You can analyze the motor neurons in people who have died of ALS, but it’s just a snapshot of things at the end.”
In a recent study, Gitler’s team utilized a mouse model of ALS to observe motor neuron changes over time, capturing how these cells transition from a healthy state to what the researchers termed “disease-associated motor neurons.” Their findings were published in a paper in the journal Cell.
This research could pave the way for novel treatments targeting the molecular mechanisms within neurons. “It gives us hope,” Gitler remarked, emphasizing the potential to detect the disease earlier and to intervene based on a better understanding of motor neuron vulnerability.
Research Highlights
ALS primarily affects fast-firing alpha motor neurons, crucial for rapid muscle contractile responses. Gitler expressed intrigue over why only certain motor neurons are affected in ALS. To address this, he and his team created an atlas of motor neurons by sequencing the RNA of over 40,000 individual cells. This atlas is publicly available for future research.
Olivia Gautier, PhD, embarked on her dissertation project to measure gene expression changes in motor neurons as they degenerate, particularly focusing on a mouse model harboring a mutation in the SOD1 gene, which is implicated in approximately 2% of ALS cases. Gautier identified a previously unrecognized subgroup of motor neurons, termed disease-associated motor neurons (DMs), characterized by significant differences in gene expression.
The analysis revealed that while more motor neurons were transitioning into the DM state as the disease progressed, some remained unaffected. These observations suggest that the onset of disease is highly variable at the cellular level, with Gitler stating, “Cells enter this disease state at different times, or don’t.”
With the identification of DMs, the researchers aim to uncover potential targets for intervention. They studied transcription factors—proteins that govern gene expression—and found several linked to ALS, with implications extending beyond the SOD1 mutation to other forms of the disease.
Gitler noted a turning point in the treatment landscape for ALS, referencing a medication approved by the FDA in 2023 that targets SOD1 RNA, alongside an experimental medicine derived from his earlier work that is in human trials. He expressed optimism that these advancements signal an evolving treatment paradigm for ALS, saying, “We’re really in an exciting time.”
As research continues, the hope is to develop therapies that prevent motor neurons from transitioning into the disease state, offering new possibilities for those affected by ALS.
